EP2915544B1 - Chimäre impfstoffe antigene gegen hepatitis c virus - Google Patents
Chimäre impfstoffe antigene gegen hepatitis c virus Download PDFInfo
- Publication number
- EP2915544B1 EP2915544B1 EP13801461.8A EP13801461A EP2915544B1 EP 2915544 B1 EP2915544 B1 EP 2915544B1 EP 13801461 A EP13801461 A EP 13801461A EP 2915544 B1 EP2915544 B1 EP 2915544B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hcv
- amino acids
- antigen
- chimeric
- antigens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091007433 antigens Proteins 0.000 title claims description 245
- 102000036639 antigens Human genes 0.000 title claims description 245
- 239000000427 antigen Substances 0.000 title claims description 243
- 241000711549 Hepacivirus C Species 0.000 title claims description 235
- 229960005486 vaccine Drugs 0.000 title claims description 61
- 150000001413 amino acids Chemical class 0.000 claims description 162
- 108010076039 Polyproteins Proteins 0.000 claims description 88
- 230000003053 immunization Effects 0.000 claims description 53
- 238000002649 immunization Methods 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 49
- 230000028993 immune response Effects 0.000 claims description 46
- 239000013612 plasmid Substances 0.000 claims description 46
- 102000004169 proteins and genes Human genes 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 101710144111 Non-structural protein 3 Proteins 0.000 claims description 40
- 108090000565 Capsid Proteins Proteins 0.000 claims description 19
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 19
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 15
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 15
- 230000006698 induction Effects 0.000 claims description 12
- 210000004698 lymphocyte Anatomy 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 description 156
- 230000003612 virological effect Effects 0.000 description 56
- 230000004044 response Effects 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 30
- 238000011725 BALB/c mouse Methods 0.000 description 29
- 229940037003 alum Drugs 0.000 description 29
- 230000000875 corresponding effect Effects 0.000 description 27
- 101710172711 Structural protein Proteins 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 23
- 102000053602 DNA Human genes 0.000 description 23
- 230000005875 antibody response Effects 0.000 description 23
- 230000009696 proliferative response Effects 0.000 description 20
- 230000000638 stimulation Effects 0.000 description 20
- 108010050904 Interferons Proteins 0.000 description 19
- 102000014150 Interferons Human genes 0.000 description 19
- 229940079322 interferon Drugs 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 18
- 230000028327 secretion Effects 0.000 description 16
- 101710132601 Capsid protein Proteins 0.000 description 14
- 238000011201 multiple comparisons test Methods 0.000 description 14
- 230000024932 T cell mediated immunity Effects 0.000 description 13
- 241000700618 Vaccinia virus Species 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 210000001672 ovary Anatomy 0.000 description 11
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 10
- 238000000540 analysis of variance Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 230000005847 immunogenicity Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 229940125575 vaccine candidate Drugs 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000700646 Vaccinia virus WR Species 0.000 description 6
- 206010058874 Viraemia Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000036755 cellular response Effects 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000004163 cytometry Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000010255 intramuscular injection Methods 0.000 description 6
- 239000007927 intramuscular injection Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000011510 Elispot assay Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 230000028996 humoral immune response Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 101710125507 Integrase/recombinase Proteins 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 241000282579 Pan Species 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108700037339 HLA-DR13 antigen Proteins 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 101710144121 Non-structural protein 5 Proteins 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 108700010756 Viral Polyproteins Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 231100000749 chronicity Toxicity 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 230000008935 histological improvement Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 102000008482 12E7 Antigen Human genes 0.000 description 1
- 108010020567 12E7 Antigen Proteins 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000950314 Figura Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710144128 Non-structural protein 2 Proteins 0.000 description 1
- 101800001020 Non-structural protein 4A Proteins 0.000 description 1
- 101800001019 Non-structural protein 4B Proteins 0.000 description 1
- 101800001014 Non-structural protein 5A Proteins 0.000 description 1
- 101710199667 Nuclear export protein Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000010273 Porphyria Cutanea Tarda Diseases 0.000 description 1
- 206010036186 Porphyria non-acute Diseases 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- SHFKGANKURXVMY-LCWPZEQJSA-N hcv e2 protein Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)CC1=CC=CC=C1 SHFKGANKURXVMY-LCWPZEQJSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24271—Demonstrated in vivo effect
Definitions
- the current invention is related to the medical field and the pharmaceutical industry, particularly, to the development of chimeric antigens against hepatitis C virus (HCV) and vaccine compositions that comprise them.
- HCV hepatitis C virus
- a minimal number of components are used because the precise selection of specific regions of HCV antigens and the inclusion of artificial epitopes, specific to CD4+ T lymphocytes, enables chimeric antigens to induce a potent and broad immune response against HCV.
- HCV infects around 3% of worldwide population Williams R. Hepatology 2006; 44: 521-526 ). Most of the infected individuals evolve to chronicity ( Amoroso P, et al., J Hepatol 1998; 28: 939-944 ). Hepatitis C infection is one of the principal causes of chronic hepatic damage, cirrhosis, liver failure and liver cancer ( Hoofnagle JH. Hepatology 2002; 36 (5 Suppl 1): S21-S29 ). Currently, HCV infection is the principal cause of liver transplantation in first world countries.
- HCV infection has been related with extra-hepatic manifestations as type II cryoglobulinemia, membranoproliferative glomerulonephritis, porphyria cutanea tarda, among others.
- a preventive vaccine against this virus is not available and the conventional antiviral treatments in use, based on the combination of pegylated interferon (IFN) + ribavirin, are effective in less than 50% of cases.
- IFN pegylated interferon
- ribavirin are effective in less than 50% of cases.
- the aforementioned treatments cause multiples adverse events ( Ghany MG et al., Hepatology. 2009; 49 (4):1335-74 ).
- HCV belongs to the Hepacivirus genus of the Flaviviridae family. It is an enveloped virus, which viral particles are around 50 and 70 nm in diameter and are associated to very low density lipoproteins (VLDL) (ffy Cl y Dubuisson J. Biol Cell. 2009; 102 (1):63-74 ).
- VLDL very low density lipoproteins
- the viral genome is a positive stranded ribonucleic acid (RNA) of approximately 9.6 kb.
- the genome encodes for a viral polyprotein that is processed co-and post-translationally in at least 10 viral proteins: Core, E1, E2, p7 (structural proteins) and nonstructural proteins: NS2, NS3, NS4A, NS4B, NS5A, NS5B ( Bartenschlager R y Lohmann V. 2000. J Gen Virol .81: 1631-48 ).
- This pathogen is an RNA virus that can rapidly mutate adapting to the host environment. This contributes to the high diversity of the multiple viral isolates identified worldwide.
- Six major HCV genotypes have been identified, which can differ up to 30% in nucleotide sequence ( Simmonds P. J Hepatol. 1999; 31 Suppl 1:54-60 ). The greatest heterogeneity is observed in the hypervariable region of HCV E2 protein, where an epitope potentially targeted by neutralizing antibodies is found. In fact, HCV circulates in the body as a heterogeneous population of viral molecules, this phenomenon is known as quasiespecies ( Simmonds P. J Gen Virol. 2004; 85 (Pt 11):3173-88 ). It has been demonstrated that mutations constitute a way of viral escape to specific humoral and cellular immune response developed by the host.
- HCV causes persistent infection in immunocompetent individuals, despite the occurrence of an active immune response ( Lechmann et al., Semin Liver Dis 2000, 20, 211-226 ).
- active immune response Lechmann et al., Semin Liver Dis 2000, 20, 211-226 .
- viral effects that contribute to the persistence of the infection, by encouraging irrelevant immune responses and preventing an effective immune response, have been elucidated. These effects are detected over both innate and acquired immunity ( Grakoui A et al. Science 2003, 302 (5645): 659-62 ).
- Grakoui A et al. Science 2003, 302 (5645): 659-62 There are evidences supporting that an ineffective immune response against HCV, not only fails to eliminate this pathogen, but it also contributes to liver damage.
- a subunit protein vaccine candidate was one of the first strategies evaluated to obtain an HCV vaccine. Some of those candidates based on structural antigens have achieved limited protection against viral challenges in animal models. Such is the case of chimpanzees immunized with an E1 and E2 oligomer. Seven chimpanzees were immunized, five of them became protected and two became infected, but then cleared the virus without reaching chronicity ( Choo et al., Proc Natl Acad Sci USA 1994, 91, 1294-1298 ). This protection correlated with the presence of antibodies able to inhibit the interaction between E2 protein and human cells ( Rosa et al., Proc Natl Acad Sci USA 1996, 93, 1759-1763 ).
- immunotherapeutic compositions Uses of other immunotherapeutic compositions are described in US 2011/0256098 A1 , wherein the immunotherapeutic compositions are used in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the treatment of chronic hepatitis C virus (HCV) infection and related conditions.
- SOC Standard of Care
- HCV antigens are employed in these immunotherapeutic compositions.
- DNA immunization has been extensively studied as a strategy for HCV vaccine development. Studies in animal models have showed the capacity of these candidates to induce cellular and humoral immune responses against almost all HCV antigens ( Alvarez-Lajonchere L, Duenas-Carrera S, Hum Vaccin. 2009; 5 (8):568-71 ). Two vaccine candidates that include DNA immunization plasmids containing sequences encoding HCV antigens are in clinical trials in humans ( Alvarez-Lajonchere L, Due ⁇ as-Carrera S, Int Rev Immunol. 2012; 31 (3):223-42 ).
- it is a DNA vaccine expressing NS3 to NS5 proteins, administered by electroporation ( Sonllberg M, et al., Expert Opin Biol Ther. 2009; 9 (7):805-15 ).
- it is a vaccine composition based on the mixture of a recombinant core protein and a DNA plasmid that expresses HCV structural antigens ( Castellanos M, et al., J Gene Med. 2010; 12 (1):107-16 ). Both candidates have demonstrated to be safe, well tolerated and have induced specific immune responses in immunized subjects ( Alvarez-Lajonchere L, Due ⁇ as-Carrera S, Int Rev Immunol. 2012; 31 (3):223-42 ).
- DNA vaccines despite their potential advantages related to their simplicity and stability, face important regulatory challenges. Their principal limitation seems to be related to their insufficient immunogenicity in humans, phenomenon not completely understood so far, and that differs considerably with the results obtained in animal models. According to the aforementioned elements, the development of a prophylactic or therapeutic vaccine against HCV is an unsolved problem.
- the present invention is directed precisely towards this goal.
- a chimeric vaccine antigen against hepatitis C virus which comprises: a) a first segment corresponding to E2 region (amino acids 408-540) of HCV polyprotein, b) a second segment corresponding to E1 region (amino acids 190-222) of HCV polyprotein, and c) a third segment corresponding to Core region (amino acids 1-50) of HCV polyprotein, in that order.
- HCV hepatitis C virus
- the novelty of the invention lies on the specific selection of epitopes and the order in which they are placed on the generated protein variants.
- This vaccine antigen's design makes possible to reduce the number of components needed to broaden and potentiate the immune response spectrum against different HCV antigens.
- a fusion protein comprising in a single chimeric antigen HCV polyprotein regions corresponding to E2 (amino acids 408-540), E1 (amino acids 190-222) and Core (amino acids 1-50) particularly in that order.
- E2 amino acids 408-540
- E1 amino acids 190-222
- Core as amino acids 1-50
- the selection of specific regions of HCV avoids the use of those regions from viral proteins that may exert immune suppressive effects. Likewise it avoids the use of other regions that may be immune dominant over those selected in the present invention and which, if included in the designed antigen, would limit the induction of specific immune response against the regions selected in the present invention.
- the invention includes the order in which the selected regions are placed in the artificial protein antigen, given the fact that this element significantly influences the induction of the immune response against HCV, due to differences in epitope exposition and processing/presentation to the immune system.
- the regions from core, E1 and E2 proteins are placed in inverse order respecting that of the native viral polyprotein.
- the sequence of the chimeric vaccine antigen is selected among the group composed of SEQ ID No. 10 (Eq1 antigen) and SEQ ID No. 16 (Eq1 b antigen).
- the chimeric antigens of the invention may additionally include in their sequence at least one T helper lymphocyte-specific epitope.
- the T helper lymphocyte-specific epitope included in the chimeric antigens is one epitope from HCV nonstructural proteins.
- the nonstructural protein is NS3. More particularly, the invention provides a chimeric vaccine antigen characterized by the amino acid sequence identified as SEQ ID No. 14 (EqNS3 antigen).
- the T helper lymphocyte-specific epitope included in the chimeric antigens is a CD4+ T lymphocyte artificial epitope.
- the term artificial epitope defines an epitope which amino acid sequence does not exist in a natural form; instead it is designed by bioinformatics.
- the selection and inclusion of the artificial epitopes, which are recognized by T helper lymphocytes, contributes to the induction of a specific immune response against the HCV epitopes included in the chimeric antigenic variants.
- artificial epitopes for T helper lymphocytes epitopes are P1M (SEQ ID No. 17) and P2B (SEQ ID No. 18).
- T helper lymphocyte specific epitope which amino acid sequence corresponds to that identified as SEQ ID No. 17 or SEQ ID No. 18.
- the chimeric antigens contain an amino acid sequence which is selected from the group composed of SEQ ID No. 12 (NSEq2 antigen), SEQ ID No. 13 (EqNSb antigen) and SEQ ID No. 15 (EqP1 antigen), and they contain at least one of these T helper lymphocyte specific epitopes.
- the following chimeric antigens have the characteristics summarized below:
- the chimeric antigen Eq1 (SEQ ID No. 10) comprises the regions E2 (amino acids 408-540), E1 (amino acids 190-222) and Core (amino acids 1-50) of the HCV polyprotein in that particular order.
- the chimeric antigen NSEq2 (SEQ ID No. 12) includes epitopes P2B and P1M, in that order, inserted on Eq1, between E1 (amino acids 190-222) and Core (amino acids 1-50) regions.
- the chimeric antigen EqNSb (SEQ ID No.
- the chimeric antigen EqNS3 includes amino acid regions 1242-1415 of the HCV polyprotein inserted on Eq1, between E1 (amino acids 190-222) and Core (amino acids 1-50) regions.
- the chimeric antigen EqP1 includes P1M epitope, inserted in Eq1, between E1 (amino acids 190-222) and Core (amino acids 1-50) regions.
- the chimeric antigen Eq1b (SEQ ID No.
- E2 amino acids 408-540
- E1 amino acids 190-222
- Core amino acids 1-50 regions of HCV polyprotein, in that particular order, but in that case the amino acids sequence corresponds to HCV genotype 1 a H77 variant (NCBI Reference Sequence: NC_004102.1).
- chimeric antigens were obtained by recombinant DNA technology, from bacteria transformed with the plasmids described in Example 1. Nevertheless, experts in this technique know that such antigens may be obtained from other hosts and may be purified by widely known procedures, to be used for immunization.
- the invention provides a vaccine composition
- a vaccine composition comprising a chimeric vaccine antigen against HCV which is composed of a) a first segment consisting of E2 region (amino acids 408-540) of HCV polyprotein, b) a second segment consisting of E1 region (amino acids 190-222) of HCV polyprotein and c) a third segment consisting of Core region (amino acids 1-50) of HCV polyprotein, in that order; and pharmaceutically acceptable excipients and/or adjuvants.
- the vaccine composition comprises the antigens identified as SEQ ID No. 10 (Eq1 antigen), SEQ ID No. 16 (Eq1b antigen), SEQ ID No. 14 (EqNS3 antigen), SEQ ID No. 12 (NSEq2 antigen), SEQ ID No. 13 (EqNSb antigen) or SEQ ID No. 15 (EqP1 antigen).
- a wide range of pharmaceutically acceptable adjuvants which are commercially available or those on development stages, may be used to potentiate the immune response against the chimeric antigens contained in the vaccine compositions object of the invention.
- the vaccine compositions of the invention may as well comprise a recombinant protein variant of HCV structural or NS3 antigens. Additionally, the vaccine compositions of the invention may comprise a plasmid for DNA immunization, which expresses HCV structural antigens. In another realization of the invention, the chimeric antigens may be formulated with a plasmid for DNA immunization, which expresses HCV structural antigens and a HCV recombinant capsid protein, simultaneously.
- the invention includes that the vaccine composition which comprises a vaccine chimeric antigen against HCV including: a) a first segment consisting of E2 region (amino acids 408-540) of HCV polyprotein, b) a second segment consisting of E1 region (amino acids 190-222) of HCV polyprotein and c) a third segment consisting of Core region (amino acids 1-50) of HCV polyprotein, in that order, may be administered on prime/boost schedules, along with preparations based on plasmids for DNA immunization, recombinant variants of HCV structural proteins or a mixture of both.
- a vaccine chimeric antigen against HCV including: a) a first segment consisting of E2 region (amino acids 408-540) of HCV polyprotein, b) a second segment consisting of E1 region (amino acids 190-222) of HCV polyprotein and c) a third segment consisting of Core region (amino acids 1-50) of HCV
- the vaccine compositions which are objects of the present invention have the advantage of inducing both humoral and cellular immune responses against several HCV antigens, therefore they are active against a wide spectrum of viral isolates and are capable of inducing protection in a surrogate viral challenge model.
- the vaccine compositions may be administered by the intramuscular, intradermal, intraperitoneal, subcutaneous, intramucosal, intravenous or sublingual routes, or any other route known by experts in the field.
- the administration may be by means of syringes, spray or any other administration devises.
- the invention also provides a chimeric vaccine antigen, or vaccine composition comprising it, for use according to claim 11. Also described herein is the use of the chimeric vaccine antigens composed of a first segment consisting of E2 region (amino acids 408-540) of HCV polyprotein, a second segment consisting of E1 region (amino acids 190-222) of HCV polyprotein and a third segment consisting of Core region (amino acids 1-50) of HCV polyprotein, in that order, for the fabrication of a vaccine to induce of an immune response against HCV. Described herein is that the aforementioned vaccine is capable of inducing protection in vivo in a surrogate viral challenge model.
- the vaccines of the invention are capable of inducing responses in healthy individuals or in HCV infected patients. Therefore, described herein is a method for the induction of immune response against HCV.
- This method is characterized by the administration of the chimeric antigen composed of a first segment consisting of E2 region (amino acids 408-540) of HCV polyprotein, a second segment consisting of E1 region (amino acids 190-222) of HCV polyprotein and a third segment consisting of Core region (amino acids 1-50) of HCV polyprotein, in that order, or a vaccine composition which contains the aforementioned antigen, to a healthy or HCV infected individual.
- the chimeric vaccine antigen, or the vaccine composition that contains it is administered on prime/boost schedules with preparations based on plasmids for DNA immunization, recombinant variants of HCV structural antigens or a mixture of both.
- the antigens of the invention or the vaccine compositions that contain them may be administered simultaneously with the medicaments included on the standard of care for this type of patients.
- Example 1 Generation of different chimeric antigens including HCV epitopes
- plMCo64K SEQ ID No. 1
- plME64K SEQ ID No. 2
- plME164K SEQ ID No. 3
- plNSE64K SEQ ID No. 4
- plENSb SEQ ID No. 5
- plENS3 SEQ ID No. 6
- plMP1E64K SEQ ID No. 7
- plME64Kb SEQ ID No. 8
- These plasmids allow the expression in Escherichia coli of the chimeric antigens Coq1 (SEQ ID No. 9), Eq1 (SEQ ID No. 10), E1q1 (SEQ ID No. 11), NSEq2 (SEQ ID No.
- EqNSb SEQ ID No. 13
- EqNS3 SEQ ID No. 14
- EqP1 SEQ ID No. 15
- Eq1b SEQ ID No. 16
- the chimeric antigen Coq1 (SEQ ID No. 9) comprises the regions Core (amino acids 1-50), E1 (amino acids 190-222) and E2 (amino acids 408-540) of the HCV polyprotein, located in this particular order.
- the chimeric antigen Eq1 (SEQ ID No. 10) comprises, equally, the regions E2 (amino acids 408-540, E1 (amino acids 190-222) and Core (amino acids 1-50) of the HCV polyprotein, but in this other particular order.
- the chimeric antigen E1 q1 (SEQ ID No.
- the chimeric antigen NSEq2 (SEQ ID No. 12) includes the epitopes P2B and P1M, in this order, inserted in Eq1, between E1 (amino acids 190-222) and Core (amino acids 1-50) regions.
- the chimeric antigen EqNSb (SEQ ID No. 13) includes the epitope P2B inserted in Eq1 between E1 (amino acids 190-222) and Core (amino acids 1-50) regions.
- the chimeric antigen EqNS3 (SEQ ID No. 14) includes the region of amino acids 1242-1415 of HCV polyprotein, inserted between E1 (amino acids 190-222) and Core (amino acids 1-50) regions of the chimeric antigen Eq1.
- the chimeric antigen EqP1 (SEQ ID No. 15) includes the epitope P1M inserted in Eq1, between E1 (amino acids 190-222) and Core (amino acids 1-50) regions.
- the chimeric antigen Eq1b (SEQ ID No.
- E2 amino acids 408-540
- E1 amino acids 190-222
- Core amino acids 1-50 of HCV polyprotein, in this particular order, but in this case the amino acids sequence corresponds to the HCV strain H77, genotype 1 a (NCBI Reference Sequence: Inc_004102.1).
- the artificial epitopes P1M and P2B, included in some of the chimeric antigens were designed by bioinformatics to be recognized by human T helper lymphocytes.
- the binding motifs to HLA-DR13 and HLA-DR11 were studied, using the programs Rankpep, SYFPETHI and ProPred, in order to propose the amino acids variants per position in the artificial epitopes, according to the frequency of appearance.
- As artificial epitopes specific for T helper lymphocytes are described P1M, of 14 amino acids, which sequence is LPEYVIMVKLPSRA (SEQ ID No. 17); and P2B, of 15 amino acids, which sequence is GYKVIVLNPRVASTL (SEQ ID No. 18).
- the recombinant protein antigens For the expression of the recombinant protein antigens, competent cells of the bacterial strain E. coli GC-366 were transformed with the respective plasmids. The expression of the recombinant proteins was developed during 12 h at 37 degrees Celsius, employing minimal cell culture medium. All protein antigens comprised for protein expression, at the N-terminus, a fragment coming from P64K protein from Neisseria meningitidis , previously known for this function ( Yero D et al., Biotechnol Appl Biochem. 2006; 44 (Pt 1):27-34 ). On the other hand, the protein variants comprise at the C-terminus a six-hystidine tag with the objective to facilitate protein purification. In fact, proteins were purified through solubilization of insoluble fraction coming from cell disruption, with carbonate-bicarbonate pH 9.6 buffer, Urea 8M, and posterior metal chelating affinity chromatography.
- mice Female BALB/c mice, 8 weeks old, 16-18 g of weight, 17 animals per group, were immunized.
- the immunization groups were as follows: Group 1, chimeric antigen Coq1 formulated in Alum; Group 2, antigen E1q1 formulated in Alum; Group 3, antigen Eq1 formulated in Alum; Group 4, Alum (control group). In all cases, 20 ⁇ g of recombinant antigens were administered.
- the immunizations were carried out at weeks 0, 2 and 4, by intramuscular injection.
- mice per group were sacrificed at week 6 to study specific cellular response.
- mice per group were challenged with the recombinant vaccinia virus vvRE ( Alvarez-Lajonchere et al., Biotecnologia (2004)da 2007; 24 (3-4): 246-253 ), expressing HCV structural proteins and other 5 animals with the control vaccinia virus WR, at week 6.
- mice Five days after challenge, mice were sacrificed and the viral titer was determined in ovaries, as previously described ( Alvarez-Lajonchere et al., Biotechnol Appl Biochem. 2008; 51 (Pt 2):97-105 ).
- the specific immune response against HCV antigens is shown in Figures 3 to 5 .
- the evaluated response was detected employing recombinant variants of Core protein (amino acids 1-120, Alvarez-Obregon JC et al. Vaccine 2001; 19: 3940-3946 ), E1 (amino acids 192-340 of HCV polyprotein, Lorenzo LJ et al., Biotechnol Appl Biochem 2000; 32(2):137-143 ), and E2 (amino acids 384-680 of HCV polyprotein, Martinez-Donato et al., Mol Biotechnol.
- mice Female BALB/c mice, 8 weeks old, 16-18 g of weight, 17 animals per group were immunized.
- the immunization groups were as follows: Group 1, antigen Eq1 formulated in Alum; Group 2, antigen Eq1 mixed with the recombinant protein NS3 ( Palenzuela D et al., Biotecnolog ⁇ atianda 2006; 23: 94-98 ) formulated in Alum; Group 3, recombinant protein NS3, formulated in Alum; Group 4, Alum (control group). In all cases, 20 ⁇ g of recombinant antigen Eq1 and 10 ⁇ g of NS3 protein were administered in the corresponding groups.
- the immunizations were carried out at weeks 0, 2 and 4, by intramuscular injection.
- mice per group were sacrificed at week 6 to study specific cellular response.
- mice per group were challenged with the recombinant vaccinia virus vvRE ( Alvarez-Lajonchere et al., Biotecnolog ⁇ atianda 2007; 24 (3-4): 246-253 ), expressing HCV structural proteins and other 5 animals with the control vaccinia virus WR, at week 6.
- mice Five days after challenge, mice were sacrificed and the viral titer was determined in ovaries, as previously described.
- the specific immune response against HCV antigens is shown in Figure 7 to 9 .
- the evaluated immune response was detected employing recombinant variants of Core protein (amino acids 1-120), E1 (amino acids 192-340 of HCV polyprotein), E2 (amino acids 384-680 of HCV polyprotein), and NS3 (amino acids 1192-1457 in HCV polyprotein), as capture antigens in ELISA, or as antigens for the stimulation in the assays for determining cellular immune response.
- antibody response is induced against HCV structural antigens in the groups immunized with Eq1 individually or mixed with NS3, without statistically significant differences among them.
- mice Female BALB/c mice, 8 weeks old, 16-18 g of weight, 17 animals per group were immunized.
- the immunization groups were as follows: Group 1, Eq1 antigen formulated in Alum; Group 2, Eq1 antigen mixed with the plasmid for DNA immunization plDKE2 ( Due ⁇ as-Carrera et al., Biotechnol Appl Biochem.
- mice received 20 ⁇ g of chimeric Eq1 antigen and 10 ⁇ g of Co.120 recombinant protein in the corresponding groups. In the case of plDKE2 plasmid, 100 ⁇ g were administered in each dose. The immunizations were carried out at weeks 0, 3 and 6 by intramuscular injection.
- mice per group were sacrificed at week 8 for studying specific cellular response. Additionally, 5 animals per group were challenged with the recombinant vaccinia virus vvRE, expressing HCV structural proteins, and other 5 animals with the control vaccinia virus WR, at week 8. Five days after challenge, the mice were sacrificed and the viral titers were determined in ovaries, as previously described.
- the specific immune response against HCV antigens is shown in Figures 11 to 13 .
- the evaluated response was detected employing recombinant variants of Core protein (amino acids 1-120), E1 (amino acids 192-340 of HCV polyprotein), and E2 (amino acids 384-680 of HCV polyprotein) as capture antigens in ELISA, or as antigens for the stimulation in the assays for determining cellular immune response.
- Core protein amino acids 1-120
- E1 amino acids 192-340 of HCV polyprotein
- E2 amino acids 384-680 of HCV polyprotein
- the IFN gamma secretion response against the Core antigen was significantly superior in the group immunized with the mixture of Eq1 and Co.120 proteins with plDKE2 plasmid, with respect to the remaining groups ( p ⁇ 0.05; ANOVA and Newman-Keuls multiple comparisons tests), with the exception of the group immunized in the prime/boost schedule (Group 4).
- mice Female BALB/c mice, 8 weeks old, 16-18 g of weight, 17 animals per group were immunized.
- the immunization groups were as follows: Group 1, Eq1 antigen formulated in Alum; Group 2, mixtures of Co.120, E1.340 ( Lorenzo LJ et al., Biotechnol Appl Biochem 2000; 32(2):137-143 ) and E2.680 ( Martinez-Donato et al., Mol Biotechnol.
- mice received 20 ⁇ g of chimeric Eq1 antigen; 16.7 ⁇ g of E1 and E2 proteins, as well as 0.1 ⁇ g of Co.120 protein, in the corresponding groups.
- the immunizations were carried out at weeks 0, 2 and 4 by intramuscular injection.
- mice per group were sacrificed at week 6 for studying specific cellular response. Additionally, 5 animals per group were challenged with the recombinant vaccinia virus vvRE, expressing HCV structural proteins, and other 5 animals with the control vaccinia virus WR, at week 8. Five days after challenge, the mice were sacrificed and the viral titers were determined in ovaries, as previously described.
- the specific immune response against HCV is shown in the Figures 15 to 17 .
- the evaluated response was detected using recombinant variants of Core protein (amino acids 1-120), E1 (amino acids 192-340 of HCV polyprotein) and E2 (amino acids 384-680 of HCV polyprotein), as capture antigens in ELISA, or as antigens for the stimulation in the assays for determining cellular immune response.
- Core protein amino acids 1-120
- E1 amino acids 192-340 of HCV polyprotein
- E2 amino acids 384-680 of HCV polyprotein
- proliferative response against HCV antigens was induced in all groups, with the exception of the control, as observed in Figure 16 . No statistically significant differences among the groups were observed with respect to the proliferative response against E1 and E2. However, all groups receiving the chimeric Eq1 antigen, in any of the combinations (Groups 1 to 4), induced a proliferative response against Core significantly superior to the induced by the mixture of HCV structural proteins (Group 5) ( p ⁇ 0.05, ANOVA and Newman-Keuls multiple comparisons tests).
- the IFN gamma secretion response had a similar behavior to that observed for the proliferative response.
- group immunized with the mixture of HCV structural proteins group 5) had an IFN gamma secretion response against Core significantly lower than the induced in the groups immunized with the chimeric Eq1 antigen individually (Group 1) and the mixture of Eq1 with the HCV structural proteins (Group 4) ( p ⁇ 0.05, ANOVA and Newman-Keuls multiple comparisons tests).
- Example 6 Immunogenicity study in mice of different chimeric antigens comprising HCV epitopes and artificial epitopes specific for T helper lymphocytes
- mice Female BALB/c mice, 8 weeks old, 16-18 g of weight, 17 animals per group were immunized.
- the immunization groups were as follows: Group 1, chimeric Eq1 antigen formulated in Alum; Group 2, chimeric NSEq2 antigen formulated in Alum; Group 3, chimeric EqNSb antigen formulated in Alum; Group 4, chimeric EqNS3 antigen formulated in alum; Group 5, chimeric EqP1 antigen formulated in Alum; Group 6, Alum (control). Mice received 20 ⁇ g of the recombinant chimeric antigens, in the corresponding groups.
- the immunizations were carried out at weeks 0, 2 and 4, by intramuscular injection.
- mice per group were sacrificed at week 6 for studying specific cellular response. Additionally, 5 animals per group were challenged with the recombinant vaccinia virus vvRE, expressing HCV structural proteins, and other 5 animals with the control vaccinia virus WR, at week 8. Five days after challenge, the mice were sacrificed and the viral titers were determined in ovaries, as previously described.
- the specific immune response against HCV antigens is shown in Figures 19 to 21 .
- the evaluated response was detected employing recombinant variants of Core (amino acids 1-120), E1 (amino acids 192-340 of HCV polyprotein), E2 (amino acids 384-680 of HCV polyprotein) and NS3 (amino acids 1192 to 1457 in the HCV polyprotein) proteins, as capture antigens in ELISA, or as antigens for stimulation in the assays for determining cellular immune response.
- a specific antibody response was induced against HCV structural proteins, without statistically significant differences among the groups immunized with the different chimeric antigens. Only the groups 2, 3 and 4, comprising regions of HCV NS3 induced antibody response against this viral antigen, being significantly superior in the Group 4 with respect to the Groups 2 and 3 ( p ⁇ 0.05, ANOVA and Newman-Keuls multiple comparison tests).
- mice Female BALB/c mice, 8 weeks old, 16-18 g of weight, 17 animals per group were immunized.
- the immunization groups were as follows: Group 1, chimeric Eq1 b antigen formulated in Alum; Group 2, chimeric Eq1 antigen formulated in Alum; Group 3, Alum (control). Mice received 20 ⁇ g of chimeric antigens, in the corresponding groups.
- the immunizations were carried out at weeks 0, 2 and 4, by intramuscular injection.
- mice per group were sacrificed at week 6 for studying specific cellular response. Additionally, 5 animals per group were challenged with the recombinant vaccinia virus vvRE, expressing HCV structural proteins, and other 5 animals with the control vaccinia virus WR, at week 8. Five days after challenge, the mice were sacrificed and the viral titers were determined in ovaries, as previously described.
- the specific immune response against HCV antigens is shown in Figures 23 and 24 .
- the evaluated response was detected employing recombinant variants of Core (amino acids 1-120), E1 (amino acids 192-340 of HCV polyprotein) and E2 (amino acids 384-680 of HCV polyprotein) proteins, as capture antigens in ELISA, or as antigens for the stimulation in the assays for determining cellular immune response.
- Core amino acids 1-120
- E1 amino acids 192-340 of HCV polyprotein
- E2 amino acids 384-680 of HCV polyprotein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (12)
- Chimäres Impfstoffantigen gegen das Hepatitis C-Virus (HCV), umfassend:a) einen ersten Abschnitt der E2-Region, der Abschnitt bestehend aus Aminosäuren 408-540 von HCV-Polyprotein,b) einen zweiten Abschnitt der E1-Region, der Abschnitt bestehend aus Aminosäuren 190-222 von HCV-Polyprotein, undc) einen dritten Abschnitt der Kernregion, der Abschnitt bestehend aus Aminosäuren 1 bis 50 von HCV-Polyprotein, in dieser speziellen Reihenfolge.
- Chimäres Impfstoffantigen nach Anspruch 1, wobei seine Aminosäuresequenz ausgewählt ist aus der Gruppe zusammengesetzt aus SEQ ID Nr. 10 und SEQ ID Nr. 16.
- Chimäres Impfstoffantigen nach Anspruch 1, dadurch gekennzeichnet, dass es ferner in seiner Sequenz mindestens ein zusätzliches Epitop spezifisch für T-Helfer-Lymphozyten umfasst, bevorzugt ein Epitop von nichtstrukturellen HCV-Proteinen, bevorzugt von NS3.
- Chimäres Impfstoffantigen nach Anspruch 3, dadurch gekennzeichnet, dass seine Aminosäuresequenz SEQ ID Nr. 14 ist.
- Chimäres Impfstoffantigen nach Anspruch 3, wobei das für T-Helfer-Lymphozyten spezifische Epitop ein künstliches Epitop ist, bevorzugt ausgewählt aus der Gruppe zusammengesetzt aus dem Epitop P1M von SEQ ID Nr. 17 und dem Epitop P2B von SEQ ID Nr. 18.
- Chimäres Impfstoffantigen nach Anspruch 5, dadurch gekennzeichnet, dass seine Aminosäuresequenz ausgewählt ist aus der Gruppe zusammengesetzt aus SEQ ID Nr. 12, SEQ ID Nr. 13 und SEQ ID Nr. 15.
- Impfstoffzusammensetzung, umfassend ein chimäres Impfstoffantigen gegen HCV, umfassend: a) einen ersten Abschnitt der E2-Region, der Abschnitt bestehend aus Aminosäuren 408-540 von HCV-Polyprotein, b) einen zweiten Abschnitt der E1-Region, der Abschnitt bestehend aus Aminosäuren 190-222 von HCV-Polyprotein, und c) einen dritten Abschnitt der Kernregion, der Abschnitt bestehend aus Aminosäuren 1 bis 50 des HCV-Polyproteins, in dieser speziellen Reihenfolge; und Exzipienten und/oder pharmazeutisch verträgliche Hilfsstoffe, bevorzugt umfassend ein chimäres Impfstoffantigen nach einem der Ansprüche 2 bis 6.
- Impfstoffzusammensetzung nach Anspruch 7, die zusätzlich eine rekombinante Proteinvariante von strukturellen HCV-Antigenen oder das HCV NS3-Antigen umfasst.
- Impfstoffzusammensetzung nach Anspruch 7, die zusätzlich ein Plasmid für DNA-Immunisierung, exprimierend die strukturellen HCV-Antigene, und bevorzugt ein rekombinantes Kapsidprotein von HCV umfasst.
- Impfstoffzusammensetzung nach Anspruch 7, die in Prime-/ Boost-Zeitplänen mit Zubereitungen basierend auf Plasmiden für DNA-Immunisierung, rekombinanten Proteinen von strukturellen HCV-Antigenen oder einem Gemisch aus beiden verabreicht werden kann.
- Chimäres Impfstoffantigen nach einem der Ansprüche 1 bis 6 oder dieses enthaltende Impfstoffzusammensetzung, zur Verwendung in einem Verfahren zur Induktion einer spezifischen Immunreaktion gegen HCV in einem gesunden Individuum oder in einem Patienten, infiziert mit HCV.
- Chimäres Impfstoffantigen oder dieses enthaltende Impfstoffzusammensetzung, zur Verwendung nach Anspruch 11, dadurch gekennzeichnet, dass solch ein chimäres Impfstoffantigen oder solch eine Impfstoffzusammensetzung zur Verabreichung in Prime-/ Boost-Zeitplänen mit Zubereitungen, basierend auf Plasmiden für DNA-Immunisierung, rekombinanten Proteinen von strukturellen HCV-Antigenen oder einem Gemisch aus beiden, bestimmt ist.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20120153A CU24112B1 (es) | 2012-11-05 | 2012-11-05 | Antígenos vacunales quiméricos contra el virus de la hepatitis c |
PCT/CU2013/000006 WO2014067498A1 (es) | 2012-11-05 | 2013-10-28 | Antígenos vacunales quiméricos contra el virus de la hepatitis c |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2915544A1 EP2915544A1 (de) | 2015-09-09 |
EP2915544B1 true EP2915544B1 (de) | 2017-08-09 |
Family
ID=49724426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13801461.8A Active EP2915544B1 (de) | 2012-11-05 | 2013-10-28 | Chimäre impfstoffe antigene gegen hepatitis c virus |
Country Status (15)
Country | Link |
---|---|
US (1) | US9676825B2 (de) |
EP (1) | EP2915544B1 (de) |
JP (1) | JP6259831B2 (de) |
KR (1) | KR102093495B1 (de) |
CN (1) | CN104837498B (de) |
AR (1) | AR093341A1 (de) |
AU (1) | AU2013339846B2 (de) |
CA (1) | CA2901346C (de) |
CU (1) | CU24112B1 (de) |
ES (1) | ES2644801T3 (de) |
IN (1) | IN2015DN03925A (de) |
MX (1) | MX358507B (de) |
RU (1) | RU2639504C2 (de) |
WO (1) | WO2014067498A1 (de) |
ZA (1) | ZA201503036B (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10300131B2 (en) | 2015-07-07 | 2019-05-28 | The Governors Of The University Of Alberta | Hepatitis C virus immunogenic compositions and methods of use thereof |
EP3515483A4 (de) * | 2016-09-21 | 2020-12-16 | The Governors of the University of Alberta | Immunogene zusammensetzungen des hepatitis-c-virus und verfahren zur verwendung davon |
CA3061326A1 (en) | 2017-04-27 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus |
CA3093314A1 (en) | 2018-03-16 | 2019-09-19 | The Governors Of The University Of Alberta | Hepatitis c virus peptide compositions and methods of use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2391843C (en) * | 1999-11-19 | 2011-10-18 | Csl Limited | Hcv vaccine compositions |
US6544780B1 (en) * | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
CU23496A1 (es) * | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
EP1981537B1 (de) * | 2006-01-04 | 2015-08-26 | GlaxoSmithKline Biologicals S.A. | HCV E1E2 protein mit MF59 Adjuvans plus HCV E1E2 kodierendem Alphavirus Vektor zur Stimulierung HCV-spezifischer T Zellen. |
US7256008B2 (en) | 2006-01-06 | 2007-08-14 | Abbott Laboratories | Determination of concentration of FK778 by competitive immunoassay |
WO2009056535A2 (en) * | 2007-10-29 | 2009-05-07 | Genimmune N.V. | Methods and kits for inducing a ctl response using a prime boost regimen |
WO2009131203A1 (ja) * | 2008-04-25 | 2009-10-29 | 東レ株式会社 | C型肝炎ウイルス由来のキメラ遺伝子を含む核酸 |
JP2012503011A (ja) * | 2008-09-19 | 2012-02-02 | グローブイミューン,インコーポレイテッド | 慢性c型肝炎ウイルス感染の免疫療法 |
WO2010047830A2 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | Agents for hcv treatment |
-
2012
- 2012-11-05 CU CU20120153A patent/CU24112B1/es active IP Right Grant
-
2013
- 2013-10-28 ES ES13801461.8T patent/ES2644801T3/es active Active
- 2013-10-28 KR KR1020157012656A patent/KR102093495B1/ko active IP Right Grant
- 2013-10-28 RU RU2015121429A patent/RU2639504C2/ru not_active IP Right Cessation
- 2013-10-28 MX MX2015005651A patent/MX358507B/es active IP Right Grant
- 2013-10-28 US US14/440,443 patent/US9676825B2/en active Active
- 2013-10-28 IN IN3925DEN2015 patent/IN2015DN03925A/en unknown
- 2013-10-28 WO PCT/CU2013/000006 patent/WO2014067498A1/es active Application Filing
- 2013-10-28 CN CN201380064380.9A patent/CN104837498B/zh active Active
- 2013-10-28 CA CA2901346A patent/CA2901346C/en not_active Expired - Fee Related
- 2013-10-28 EP EP13801461.8A patent/EP2915544B1/de active Active
- 2013-10-28 JP JP2015540044A patent/JP6259831B2/ja not_active Expired - Fee Related
- 2013-10-28 AU AU2013339846A patent/AU2013339846B2/en not_active Ceased
- 2013-11-04 AR ARP130104019A patent/AR093341A1/es unknown
-
2015
- 2015-05-04 ZA ZA2015/03036A patent/ZA201503036B/en unknown
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
ZA201503036B (en) | 2016-01-27 |
MX2015005651A (es) | 2015-08-20 |
KR20150079694A (ko) | 2015-07-08 |
JP6259831B2 (ja) | 2018-01-10 |
AR093341A1 (es) | 2015-06-03 |
MX358507B (es) | 2018-08-22 |
US20150307558A1 (en) | 2015-10-29 |
US9676825B2 (en) | 2017-06-13 |
CN104837498A (zh) | 2015-08-12 |
KR102093495B1 (ko) | 2020-03-26 |
CU24112B1 (es) | 2015-08-27 |
RU2639504C2 (ru) | 2017-12-21 |
EP2915544A1 (de) | 2015-09-09 |
IN2015DN03925A (de) | 2015-10-02 |
WO2014067498A1 (es) | 2014-05-08 |
JP2015536936A (ja) | 2015-12-24 |
CN104837498B (zh) | 2018-05-18 |
AU2013339846B2 (en) | 2017-08-17 |
CA2901346A1 (en) | 2014-05-08 |
RU2015121429A (ru) | 2016-12-27 |
ES2644801T3 (es) | 2017-11-30 |
AU2013339846A1 (en) | 2015-05-14 |
CA2901346C (en) | 2019-04-23 |
CU20120153A7 (es) | 2014-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zingaretti et al. | Why is it so difficult to develop a hepatitis C virus preventive vaccine? | |
EP2915544B1 (de) | Chimäre impfstoffe antigene gegen hepatitis c virus | |
EP2124993A1 (de) | Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung | |
Olivera et al. | Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice | |
KR101245154B1 (ko) | 간염 c 바이러스에 대한 백신 조성물 | |
US8691234B2 (en) | Vaccine formulation potentiated by the combination of DNA and an antigen | |
AU746258B2 (en) | Genetic immunization with nonstructural proteins of hepatitis C virus | |
US20070032444A1 (en) | Genetic immunization with nonstructural proteins of hepatitis C virus | |
EP3432923B1 (de) | Hcv-impfstoffe | |
Abrignani et al. | Hepatitis C vaccines | |
RU2353651C2 (ru) | Рекомбинантные векторы на основе "живого" вируса оспы домашней птицы и их применение в фармацевтических композициях против вируса гепатита с | |
JP2008508890A6 (ja) | 組換え生鶏痘ウィルスベクター及びc型肝炎ウィルスに対する薬剤組成物中でのそれらの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150605 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
17Q | First examination report despatched |
Effective date: 20160519 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170228 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 916100 Country of ref document: AT Kind code of ref document: T Effective date: 20170815 |
|
GRAT | Correction requested after decision to grant or after decision to maintain patent in amended form |
Free format text: ORIGINAL CODE: EPIDOSNCDEC |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013024868 Country of ref document: DE |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2644801 Country of ref document: ES Kind code of ref document: T3 Effective date: 20171130 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20170809 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 916100 Country of ref document: AT Kind code of ref document: T Effective date: 20170809 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171109 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171110 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171209 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171109 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 26252 Country of ref document: SK |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013024868 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20180511 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171028 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20171031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171028 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171028 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20131028 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20191011 Year of fee payment: 7 Ref country code: DE Payment date: 20191021 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20191028 Year of fee payment: 7 Ref country code: ES Payment date: 20191126 Year of fee payment: 7 Ref country code: IT Payment date: 20191028 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20191021 Year of fee payment: 7 Ref country code: TR Payment date: 20191021 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20191021 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170809 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602013024868 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20201028 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: MM4A Ref document number: E 26252 Country of ref document: SK Effective date: 20201028 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201031 Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201028 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201031 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201028 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201028 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201029 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201028 |